Get Template

Document Sample
Get Template Powered By Docstoc
					Title goes in this area.
Subhead as needed.

January 19, 2004
Title Text 36 pt Arial bold                                           (not all Caps)


Subtitle 30 pt Arial bold, Italics                                        (not all caps)




 •   Title/subtitle text box must be positioned left justified The template
     automatically positions a one-line title
       Titles with 2+ lines require text box adjustment.
       To adjust text box position:
             Select title text box (hold down shift key and select)
             Move up/down using arrow keys (hold the Ctrl key while using arrow keys to adjust in
               small increments)

 Line spacing between title and subtitle is “1 line”
 Subtitle line is in yellow-green.




<add venue and date here>
Body/Bulleted Text Guidelines
Level 1 font: Arial 30 pt, white
    Level 2 font: Arial 26 pt, white
            Level 3 font: Arial 22 pt, white
            •Bullet: at 100%, Color: white
                        Level 4, font: Arial 18 pt, white
                        • Bullet: at 100%, Color: white




<add venue and date here>
    Color Palette (RGB)
    Numbers are RGB (red-green-blue) equivalents
    Green/yellow                      Orange/Red                      White / Grey                       Blue
                        247                              250                            255                               0
                        252                              158                            255                              153
                        144                               13                            255                              153

                        153                                                             153
                                                          87                                                              87
                        204                    2                                        204
                                                          44                                                              137
                          0                                                             204
                                                          03                                                              255

                         0
                                                         255
                        102
                                                          0
                         0                                0




If colors from the palette above do not appear on PowerPoint’s dynamic color palette, they may be added in either of
the following 2 ways:
• Select the desired color from the palette above -> fill color -> more fill colors -> the desired color will appear in the
colors dialogue box palette as the new color -> OK. The new color will now appear on the rotating (dynamic) palette.
• Select the object to be colored -> fill, line, or text color -> more colors -> custom -> enter Red, Green, & Blue numbers
listed to the right of the desired color above -> OK . The new color will now appear on t he rotating (dynamic) palette.




    <add venue and date here>
Bar Chart Guidelines
 90                                              Font (axis labels &
 80                                              legend)
 70                                              Font: NewGoth BD BT
                                                 appropriate
 60                                              Color & size: white, 14
                                         East
 50                                              pt. or larger
                                         West
 40                                              Axis lines & ticks
                                         North
                                                 Width: 1 pt
 30
                                         South   Color: white
 20
                                                 Fill & data bars
 10                                              Use no background fill
  0                                              Bar width: set as
       1st Qtr 2nd Qtr 3rd Qtr 4th Qtr           desired,
                                                 keep moderate



<add venue and date here>
Sample Slides
The following slides are taken from
  Cephalon’s corporate presentation and are
  included for your use where appropriate and
  as examples of how the template should be
  used.




<add venue and date here>
Cephalon

Annual Stockholder Meeting
May 13, 2004
Safe Harbor Statement
This presentation contains forward-looking statements
that involve risks and uncertainties. These statements
may concern, among other things, our business
strategy and market opportunities, the development of
pharmaceutical products, and future financial and
operating results.
Additional information that may affect our business and
financial prospects, as well as factors that would cause
our actual performance to vary from our expectations,
may be found in our filings with the Securities and
Exchange Commission.


<add venue and date here>
Cephalon Today
Achieving The Right Balance
• Fully integrated, biotech-based pharmaceutical company
• Focus on research and development
• Major presence in the United States and Europe
• Three key products marketed in the United States
• Rapid growth
• Generating significant cash flow
• More than $1 billion in cash available


 <add venue and date here>
     A Rapidly Growing Product Portfolio
     5 Year CAGR of 75%
         $1,000
          $900
          $800
          $700                                                                       Other Products
 Sales




          $600                                                                       Gabitril
Sales




          $500                                                                       Actiq
                                                                                     Provigil
          $400
          $300
          $200
          $100
            $0
                   1998          1999   2000     2001      2002        2003   2004
     Note that 2004 figures reflect Cephalon’s most recent guidance.
     <add venue and date here>
Provigil
Creating The Wakefulness Market




<add venue and date here>
                   Provigil Sales (40% CAGR)
                     $400                                                                                           450,000
                                                                                                           1Q04
                                                                                                    4Q03
                     $350                                                                    3Q03                   400,000
                                                                                      2Q03
                     $300
                                                                                                                    350,000
Sales (Millions)




                                                                        4Q02   1Q03




                                                                                                                                Prescriptions
                                                                 3Q02                                               300,000
                     $250                                 2Q02

                                                   1Q02                                                             250,000
                     $200                   4Q01
                                    3Q01                                                                            200,000
                             2Q01
                     $150
                                                                                                                    150,000
                     $100
                                                                                                                    100,000
                       $50                                                                                          50,000

                        $0                                                                                          0
                                           2001                     2002                       2003               Source: IMS


                   <add venue and date here>
 Gabitril - Novel Mechanism of Action
 For Partial Seizures, a form of Epilepsy




<add venue and date here>
                   Gabitril Sales (60% CAGR)
                   $80                                                                                 1Q04   220,000
                                                                                                4Q03
                                                                                                              200,000
                   $70
                                                                                         3Q03
                                                                                                              180,000
                                                                                  2Q03
Sales (Millions)




                   $60
                                                                                                              160,000




                                                                                                                        Prescriptions
                                                                    4Q02   1Q03

                   $50                                       3Q02
                                                                                                              140,000
                                                                                                              120,000
                   $40                                2Q02
                                                                                                              100,000
                                               1Q02
                   $30                                                                                        80,000
                                        4Q01
                                 3Q01
                   $20
                                                                                                              60,000
                          2Q01
                                                                                                              40,000
                   $10
                                                                                                              20,000
                    $0                                                                                        0
                                    2001                       2002                        2003
                                                                                                              Source: IMS


                   <add venue and date here>
Actiq
For Breakthrough Cancer Pain




<add venue and date here>
                   Actiq Sales (110% CAGR)
                   $300                                                                                        110,000
                                                                                                        1Q04
                                                                                                 4Q03          100,000
                                                                                          3Q03
                   $250
                                                                                                               90,000
Sales (Millions)




                                                                                   2Q03                        80,000




                                                                                                                         Prescriptions
                   $200
                                                                            1Q03
                                                                                                               70,000
                                                                     4Q02
                                                                                                               60,000
                   $150                                       3Q02
                                                                                                               50,000
                                                       2Q02

                   $100                         1Q02
                                                                                                               40,000
                                         4Q01
                                                                                                               30,000
                                  3Q01
                     $50   2Q01                                                                                20,000
                                                                                                               10,000
                      $0                                                                                       0
                                      2001                      2002                        2003               Source: IMS


                   <add venue and date here>
Cephalon 2003 Results

 Industry leading sales and earnings growth:

                                                           2003
Revenue                                                    $715 million (41% growth)
Product Sales                                              $685 million (47% growth)
EPS                                                        $1.54*
Cash & Investments                                         $1.2 billion

 * For the reconciliation of GAAP diluted EPS to adjusted diluted EPS,
 see the press release dated 2/12/04 at www.cephalon.com.



<add venue and date here>
Cephalon Relative Stock Performance
  150.00%


                                                                  CEPH
  140.00%




  130.00%




  120.00%




  110.00%

                                                                                            Cephalon
                                                                                            Amex Biotechnology Index
  100.00%
                                                                                            Nasdaq Composite Index
                                                                                            Nasdaq Index - Biotech
                                                                                            S&P 500 Index
   90.00%
            Apr-03 May-03   Jun-03   Jul-03   Aug-03   Sep-03   Oct-03   Nov-03   Dec-03   Jan-04   Feb-04   Mar-04   Apr-04




<add venue and date here>
2004 Deliverables

• Sales guidance of $900-950 million (35% growth)
• Diluted adjusted EPS* guidance of $2.00/share (30% growth)
• Launch expanded Provigil label in the United States
• Substantial investment in clinical research
• New data in Gabitril-anxiety, Provigil-ADHD, Nuvigil-ES


* For the reconciliation of projected GAAP diluted EPS to adjusted diluted EPS guidance see the
 press release dated 2/12/04 at www.cephalon.com.




 <add venue and date here>
Great Start to 2004
U.S. FDA Approves Expanded Label for Provigil
January 2004
Provigil is indicated to improve wakefulness in patients with
excessive sleepiness associated with narcolepsy, obstructive
sleep apnea/hypopnea syndrome, and shift work sleep disorder.


UK MCA Approves Expanded Label for Provigil
April 2004
Provigil is indicated for treatment of excessive sleepiness in patients
with chronic pathological conditions, including narcolepsy,
obstructive sleep apnea/hypopnea syndrome and moderate to severe
chronic shift work sleep disorder.



  <add venue and date here>
Provigil
U.S. & UK Launch Underway
• Increased U.S. sales force to 500 in 2004
     • Physician call universe expanded to include 75,000
       U.S. physicians
     • Calling on thousands of primary care physicians for the
       first time

• UK label is broadest ever for Provigil
     • Doubled the UK sales force in 2004
     • Calling on psychiatrists for the first time




<add venue and date here>
  Investment In Clinical Research
  A Dramatic Increase In 2004
                              2000      2002              2004
  Patients in trials           450       800               3400
                 Phase 2                  Registration Studies
Gabitril - GAD                       Nuvigil – OSA/HS, narcolepsy
Gabitril - insomnia                  Provigil ADHD
CEP-701 - AML                        Actiq Sugar Free - acute pain
CEP-701 - prostate cancer            OraVescent® fentanyl - acute pain*
                                     Gabitril – anxiety
                                     CEP-1347 - Parkinson’s disease

                                               * Pending CIMA LABS INC. merger



  <add venue and date here>
    Pipeline Compounds
    CEP-1347 for Parkinson’s Disease
  •    Completed enrollment in 800-patient study
  •    Each patient in study for 2 years
  •    Double-blind, placebo-controlled
  •    Endpoints:
         • Lengthening the time to dopaminergic therapy
         • SPECT imaging
  • Expected completion of study 2006
  • Wang et al, Mixed Lineage Kinases
         • Annual Rev. Pharmacol. Toxicol. 44:451-74



<add venue and date here>
Aggressive M&A Strategy
CIMA LABS INC.
• Proven leader in drug delivery technology
     • Established profitable base business
     • $76 million in 2003 annual revenue with expected
       growth of 12% per year
• Exciting proprietary OraVescent® technology
• OraVescent® fentanyl completed Phase II
     • Maximize this opportunity with our clinical, regulatory,
       manufacturing and commercial expertise
• Expect to complete merger in 2nd quarter 2004

<add venue and date here>
          Product Franchise Strategy
          Targeted Product Approvals
  Provigil Franchise                     2004           2005          2006 2007 2008   2009
         Provigil
         ADHD
        Nuvigil™
  2 nd Generation NCE


     Actiq Franchise
           Actiq
       Sugar Free
  OraVescent Fentanyl*
Titragesia™(CHADD™)**
     DD5 Formulation

  Gabitril Franchise
       Epilepsy
  Anxiety Disorders
      Insomnia
   Neuropathic Pain

      * Pending CIMA LABS INC. merger.   ** Being jointly developed with Zars, Inc.
     <add venue and date here>
    A Bright Future
    Proven Business Strategy

•   We are proud of our many accomplishments
•   Extraordinary sales and earnings growth
•   Ample cash positions us for new opportunities
•   Significant increase in clinical programs in 2004
•   2004 notable for a plethora of clinical data
•   Positioning Cephalon for its greatest period of
    growth in 2006 and beyond


<add venue and date here>
Annual Stockholder Meeting
May 13, 2004

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:0
posted:3/16/2013
language:English
pages:27
ihuang pingba ihuang pingba http://
About